Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Epigenetic Signature in Renal Cell Carcinoma: Predictive of Outcomes?

By: Sarah Campen, PharmD
Posted: Monday, January 18, 2021

Gang Wang, PhD, of Zhongnan Hospital of Wuhan University, Wuhan, China, and colleagues have developed an epigenetic signature that may help predict overall survival and staging of disease progression in patients with clear cell renal cell carcinoma, according to a study published in Cancer Cell International. Based on this epigenetic signature, Dr. Wang and colleagues also constructed a nomogram that may facilitate the prognosis for this patient population.

A total of 319 cases of clear cell renal cell carcinoma from The Cancer Genome Atlas database were randomly assigned to either a training set (n = 213) or a testing set (n = 106). The corresponding clinical follow-up information of all cases included the survival time, survival outcome, tumor staging, and grading. After using LASSO Cox regression analysis to perform methylation sequencing, the authors constructed a 31-CpG–based epigenetic signature. Patients were divided into two groups—high or low risk—based on their median epigenetic signature scores.

In the training set, a Kaplan-Meier survival curve analysis indicated that the high-risk group had a significantly worse prognosis than the low-risk group (hazard ratio (HR) = 13.0, 95% confidence interval = 8.0–21.2, P < .0001).  A multivariate analysis found that the epigenetic signature score (HR = 3.09, P < .0001) and pathologic stage (HR = 2.42, P = .0002) could accurately predict the overall survival rate of clear cell renal cell carcinoma independently of other factors. Based on these results, the authors also created a nomogram to “accurately and conveniently” predict the prognosis of patients with clear cell renal cell carcinoma for clinicians.

Disclosure: The authors reported no conflicts of interest.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.